Bausch Health Companies Today BHC Bausch Health Companies $8.05 -0.03 (-0.37%) 52-Week Range $3.96 ▼ $11.46 Price Target $7.33 Add to Watchlist Bausch Health NYSE: BHC stock has been on a wild ride recently, with a dramatic surge in value over the last month. The catalyst for this surge is a wave of rumors suggesting that Bausch + Lomb NYSE: BLCO, Bausch Health's spinoff eye care business, is considering a buyout. This potential sale has sparked significant interest among investors, as it could lead to a mu ...

Shares of Bausch Health, Inc. (BHC) gained 14.7% in a week on reports of refinancing its debt to enable the impending sale of its eye care company, Bausch + Lomb (BLCO) . The industry declined 0.6% during this timeframe. The sale, intended to separate both companies, is stuck for quite some time now. Hence, reports of BHC moving forward have encouraged investors. Image Source: Zacks Investment Research BHC's Plans to Separate BLCO In August 2020, BHC announced its plan to separate its eye health business, c ...

Tom Yeung here with your Sunday Digest. During the early 1990s real estate crisis, the Marriott Corp. hotel chain found itself in trouble. The company had overexpanded during the boom times of the 1980s, and the ensuing crash had left it with over a hundred unsellable hotels in an overbuilt market. To save the firm, Chief Financial Officer Stephen Bollenbach created a breakup plan for the hotel chain. Under the agreement, Marriott would keep its lucrative management business (the "good" Marriott), while spi ...

Gain access to all of the market research and financial analytics used in the preparation of this article plus exclusive content and pharma, healthcare and biotech investment recommendations and research / analytics by subscribing to my channel, Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, ...

Bausch Health (BHC) shares rallied 11.7% in the last trading session to close at $8.02. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 23.2% gain over the past four weeks. Bausch stock witnessed a rally after a Bloomberg report said that the company is working with Jefferies Financial Group to explore refinancing some of its debt. The debt refinancing is expected to help the company in the impending spinoff ...

In January, I wrote an article in which I recommended Bausch + Lomb (NYSE: BLCO ) on the grounds that it was trading near its 52-week lows and looked like a good rebound candidate. BLCO stock has I'm Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press, as well as American Conservative Magazine and the Quincy Institute for Responsible Statecraft. I have ...

CHICAGO, ILLINOIS - MAY 05: Bausch + Lomb eye vitamins are offered for sale at a drug store on May 05, 2022 in Chicago, Illinois. Bausch + Lomb parent company Bausch Health is spinning off the eye-care company with an upcoming IPO which will list on the New York Stock Exchange and TSX with the ticker symbol "BLCO". (Photo by Scott Olson/Getty Images) In May 2022 , Bausch + Lomb (BLCO) was spun off as a separate publicly traded entity, but it continues to be a core part of Bausch Health's business through it ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Bausch Health Companies Inc.'s (BHC) reported second-quarter adjusted earnings per share of 89 cents, on par with the Zacks Consensus Estimate. The reported figure increased from 81 cents in the year-ago quarter due to higher revenues. Total revenues of $2.4 billion were up 11% year over year. The top line also beat the Zacks Consensus Estimate of $2.3 billion. Excluding the impact of foreign exchange of $25 million, acquisitions of $104 million, and divestitures and discontinuations of $14 million, revenue ...

资本结构优化和业务转型 - 公司继续执行多年计划,以转型和释放价值,包括专注于产品组合、基础设施、地理足迹、资本结构和风险管理等[330] - 公司采取措施有效管理资本结构,包括采取行动减少长期债务本金余额、将资本配置于核心业务增长、提高患者获取能力、剥离资产以简化业务并持续投资可持续增长驱动因素[331] - 公司认为这些措施有助于专注业务、改善资本结构并缓解与历史诉讼相关的某些风险,有助于通过分离眼健康和制药业务释放潜在价值[332] - 公司认为分离后各实体的适当资本化和负债水平是实现资产组合价值最大化的关键目标[333] - 公司持续评估资本结构并寻求简化业务和改善资本结构的机会,以更好地专注于核心业务[341] 债务管理和融资 - 公司于2024年1月和5月通过一系列交易以现金约5.3亿美元回购并偿还5.55亿美元面值的高级无担保票据[336] - 公司于2023年9月为收购Xiidra及其他眼科资产支付17.5亿美元的首付款,通过新增5亿美元B+L定期贷款和14亿美元B+L担保票据进行融资[338] - 公司于2023年6月设立6亿美元应收账款融资额度,截至2024年6月30日已提取3亿美元[339] 新产品开发和推广 - Fraxel - Next Generation Fraxel是一种用于皮肤修复的分数激光设备，FDA提交已完成,预计将在2024年下半年获得批准[350] - CABTREO - 首个也是唯一一个获FDA批准的固定剂量三联组合外用祛痘治疗产品,已于2024年第一季度在美国上市,并于2023年5月30日向加拿大卫生部提交新药申请[351] - SiHy Daily - 一款硅水凝胶日抛隐形眼镜,旨在提供出色的舒适度和全天清晰视力,已在50多个国家推出,公司计划在2024年继续在更多国家推出该产品[352] - Lumify - 一款OTC用于缓解眼部红血丝的滴眼液,公司已在多个国家推出或获得推出权,并推出了新的延伸产品[353] - 公司正在扩展其基于enVista平台的高端人工晶状体产品线,包括enVista Aspire、enVista Envy Trifocal和enVista Beyond等[354][355] 财务业绩 - 收入增长11%,达到24.03亿美元[403] - 营业利润下降5.6%,至3.89亿美元[404] - 税前利润下降39.2%,至4800万美元[406] - 归属于Bausch Health公司的净利润下降61.5%,至1000万美元[407] - 每股基本和稀释收益分别下降至0.03美元和0.03美元[402] - 收入增长主要由于收购带来的增量销售、销量增加和定价改善[403] - 营业利润下降主要由于销售、广告和促销费用增加[404] - 税前利润下降主要由于利息费用增加和营业利润下降[406] - 净利润下降主要由于税前利润下降[407] 业务风险 - 公司正面临专利到期和仿制药竞争的风险[392][394][395]